CAS 1440964-89-5
:Formel:C20H15F3N8
InChl:InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
InChI Key:QHXLXUIZUCJRKV-UHFFFAOYSA-N
SMILES:CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
Filtern nach
Reinheitsanteil
0
100
|
0
|
50
|
90
|
95
|
100
7 Produkte gefunden.
- Niedrigster Preis
- Höchster Preis
- Niedrigste Reinheit
- Höchste Reinheit
- Schnellste Lieferung
Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formel:C20H15F3N8Reinheit:99.16%Farbe und Form:SolidMolekulargewicht:424.38196-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine
CAS:Formel:C20H15F3N8Reinheit:98%Farbe und Form:SolidMolekulargewicht:424.3819Bozitinib
CAS:6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazineFormel:C20H15F3N8Reinheit:98%Molekulargewicht:424.38Bozitinib (PLB-1001)
CAS:Bosutinib is a CDK4/6 inhibitor that inhibits the activity of proteins that regulate cell division. Bosutinib has been shown to have anti-cancer properties by inhibiting the growth of cancer cells in preclinical models. Bosutinib also inhibits epidermal growth factor (EGF) and tumor necrosis factor (TNF). Bosutinib has been shown to have clinical benefit in patients with subcutaneous tumors, glioma, and other cancers. Bosutinib has not been evaluated in pregnant women or children and should be used only if potential benefits outweigh risks.Formel:C20H15F3N8Reinheit:Min. 95%Molekulargewicht:424.38 g/mol
